What do systematic reviews say?

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes adverse events, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1.58
  2 studies · 162 participants
  Very low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 2.84 [0.96, 8.37]
  1 study · 142 participants
  Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 86 participants
  Low

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 8.73 [1.29, 59]
  1 study · 23 participants
  Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1 [0.75, 1.34]
  1 study · 20 participants
  Low

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
  RR 0.22 [0.13, 0.38]
  2 studies · 435 participants
  Moderate

Physical activity vs usual care

• Physical activity interventions for disease‐related physical and mental health during and following treatment in… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 305 participants
  Low